5/16/2018 MR Coordinating Committee Mark Rosen, MD PhD May 16, 2018 Topics of Discussion • Change in composition of BCs and TFs; role of MR CC 1
5/16/2018 Meta-analysis Performed New BCs created from legacy PDF Meta-analysis Performed 2
5/16/2018 Augment MR CC… Leverage Areas of Specialization within MR CC “Whole Body” metrics Brain metrics Joint/MSK metrics Liver metrics Meta-analysis Performed Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles 3
5/16/2018 Progressing to Profiles…and Beyond Meta-analysis Performed …stopping point of some BC activity prior to claim/clinical confirmation Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles • Challenges in anatomic specific vs. generic measurands 4
5/16/2018 DWI: brain claim DWI: liver claim “Whole Body” metrics Brain metrics DWI: prostate claim Joint/MSK metrics Liver metrics Meta-analysis Performed Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles • Challenges in anatomic specific vs. generic measurands • New biomarkers in MR? • Biomarkers vs. Phenotypes? • Multi-measurand imaging protocols (e.g liver, prostate, brain) • Role of radiomics 5
5/16/2018 CV T1 CV K trans “Whole Body” metrics Brain metrics fMRI(motor/language) Resting state fMRI Joint/MSK metrics CV T2* CV PDFF Liver metrics Meta-analysis Performed Topics of Discussion • Change in composition of BCs and TFs; role of MR CC • Plans for progression of BC activity beyond profiles • Challenges in anatomic specific vs. generic measurands • New biomarkers in MR? • Biomarkers vs. Phenotypes? • Multi-measurand imaging protocols (e.g liver, prostate, brain) • Role of radiomics • Adapting profiles for technological advancements in MR 6
5/16/2018 Profiles v2.0 in MR • DCE: re-evaluate claims for modern imaging • 3T and B1 heterogeneity • Groundwork project challenge of B1 compensation • Effect of FOV: brain vs body imaging • Vendor-specific differences in B1 mapping protocols • strong effect on VFA correlations Profiles v2.0 in MR • Next generation of MR imaging • Multi-band excitation/parallel imaging/etc. • Need to recreate claim generation process (“from scratch”?) • Metrology concern: “bias creep” in using last methodology as new ground truth • Liver examples: MRE and PDFF become the “gold standard” • FDA example: leveraging prior knowledge? 7
5/16/2018 8
Recommend
More recommend